In metastatic melanoma, NSCLC, and renal cell carcinoma, for example, patients with low PD-L1 expression and low TMB have also responded to PD-1 blockade, albeit at a much lower rate [21–23]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.